Anteris is a structural heart company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients.
Its focus is on developing next-generation technologies with world-class partners.
Durable heart valve with ADAPT®
Competing in a potential US$8 billion market, the company is developing the world’s ‘most durable heart valve’ with its ADAPT® anti-calcification treatment platform technology.
ADAPT® has unique properties that are critical to longer-lasting aortic valves and has been used in more than 20,000 patients globally.
DurAVR™, built with ADAPT® technology, is a novel and highly durable 3D single-piece aortic valve for the treatment of aortic stenosis.
DurAVR™ also has unique properties that are critical to longer-lasting valves and is now in human clinical trials following successful preclinical studies.
After successfully enrolling and discharging its first patient in a ‘first in human DurAVR™ SAVR Feasibility Clinical Study’ in April, the company has been progressing with preclinical animal studies.
A preclinical study is underway to compare anti-calcification properties of its proprietary ADAPT® treated tissue with other bovine and porcine tissues used in commercially available SAVR and TAVR valves.
Calcification plays a significant role in the failure of bioprosthetic and other tissue heart valve substitutes.
The study will be conducted in Minneapolis, USA, at a world-renowned preclinical facility with the aim being to evaluate anti-calcification properties in the established subcutaneous rat model.
Around 48 rats will be implanted and harvested implants will be processed for histological and calcium/phosphorus analysis initially at the end of four months.